- Home
- ELSE vs CANF Comparison
ELSE vs CANF Comparison
Compare ELSE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELSE
- CANF
- Stock Information
- Founded
- ELSE 1968
- CANF 1994
- Country
- ELSE United States
- CANF Israel
- Employees
- ELSE N/A
- CANF N/A
- Industry
- ELSE Industrial Machinery/Components
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ELSE Industrials
- CANF Health Care
- Exchange
- ELSE Nasdaq
- CANF Nasdaq
- Market Cap
- ELSE 13.2M
- CANF 14.8M
- IPO Year
- ELSE N/A
- CANF N/A
- Fundamental
- Price
- ELSE $4.18
- CANF $1.10
- Analyst Decision
- ELSE
- CANF Strong Buy
- Analyst Count
- ELSE 0
- CANF 2
- Target Price
- ELSE N/A
- CANF $14.00
- AVG Volume (30 Days)
- ELSE 76.9K
- CANF 82.1K
- Earning Date
- ELSE 05-12-2025
- CANF 06-10-2025
- Dividend Yield
- ELSE N/A
- CANF N/A
- EPS Growth
- ELSE 14.32
- CANF N/A
- EPS
- ELSE 0.11
- CANF N/A
- Revenue
- ELSE $9,368,000.00
- CANF $674,000.00
- Revenue This Year
- ELSE N/A
- CANF $461.72
- Revenue Next Year
- ELSE N/A
- CANF N/A
- P/E Ratio
- ELSE $38.01
- CANF N/A
- Revenue Growth
- ELSE 7.01
- CANF N/A
- 52 Week Low
- ELSE $3.65
- CANF $0.98
- 52 Week High
- ELSE $5.50
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ELSE 52.35
- CANF 46.33
- Support Level
- ELSE $3.75
- CANF $1.02
- Resistance Level
- ELSE $4.32
- CANF $1.09
- Average True Range (ATR)
- ELSE 0.29
- CANF 0.04
- MACD
- ELSE 0.03
- CANF 0.02
- Stochastic Oscillator
- ELSE 32.32
- CANF 95.83
About ELSE Electro-Sensors Inc.
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).